» Articles » PMID: 25796004

Elatoside C Protects the Heart from Ischaemia/reperfusion Injury Through the Modulation of Oxidative Stress and Intracellular Ca²⁺ Homeostasis

Overview
Journal Int J Cardiol
Publisher Elsevier
Date 2015 Mar 22
PMID 25796004
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We have previously shown that Elatoside C reduces cardiomyocyte apoptosis during ischaemia/reperfusion (I/R). Here, we investigated whether Elatoside C improves heart function in isolated rat hearts subjected to I/R and elucidated the potential mechanisms involved in Elatoside C-induced protection.

Methods And Results: Isolated rat hearts were subjected to global ischaemia followed by reperfusion in the absence or presence of Elatoside C. We found that Elatoside C significantly attenuated cardiac dysfunction and depressed oxidative stress induced by I/R. Consistently, Elatoside C prevented I/R-induced mitochondrial dysfunction, which was evident by the inhibition of mitochondrial ROS production, mitochondrial permeability transition pore (mPTP) opening, cytochrome c release from the mitochondria and Bax translocation. Moreover, Elatoside C improved abnormal calcium handling during I/R, including increasing sarcoplasmic reticulum Ca(2+) ATPase (SERCA2) activity, alleviating [Ca(2+)]ER depletion, and reducing the expression levels of ER stress protein markers. All of these protective effects of Elatoside C were partially abolished by the PI3K/Akt inhibitor LY294002, ERK1/2 inhibitor PD98059, and JAK2/STAT3 inhibitor AG490. Further assessment in isolated cardiomyocytes showed that Elatoside C maintained the Ca(2+) transients and cell shortening against I/R.

Conclusions: Elatoside C protects against cardiac injury during I/R by attenuating oxidative stress and [Ca(2+)]i overload through the activation of both the reperfusion injury salvage kinase (RISK) pathway (including PI3K/Akt and ERK1/2) and the survivor activating factor enhancement (SAFE) pathway (including JAK2/STAT3) and, subsequently, inhibiting the opening of mPTPs.

Citing Articles

Halofuginone ameliorates the susceptibility to atrial fibrillation by activating the PI3K/Akt signaling pathway.

Xu F, Zhao X, Zhang J, Shen C J Mol Histol. 2024; 55(6):1295-1306.

PMID: 39317829 DOI: 10.1007/s10735-024-10270-w.


Influence of acidic metabolic environment on differentiation of stem cell-derived cardiomyocytes.

Jiahao M, Fan Z, Junsheng M Front Cardiovasc Med. 2024; 11:1288710.

PMID: 38572303 PMC: 10987843. DOI: 10.3389/fcvm.2024.1288710.


Research progress in pharmacological effects of .

He D, Zeng L, Chen P Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023; 52(5):616-626.

PMID: 37916310 PMC: 10630058. DOI: 10.3724/zdxbyxb-2023-0147.


Dapagliflozin attenuates cardiac remodeling and dysfunction in rats with β-adrenergic receptor overactivation through restoring calcium handling and suppressing cardiomyocyte apoptosis.

Liu T, Wu J, Shi S, Cui B, Xiong F, Yang S Diab Vasc Dis Res. 2023; 20(4):14791641231197106.

PMID: 37589258 PMC: 10437211. DOI: 10.1177/14791641231197106.


Hypothermic oxygenated perfusion attenuates DCD liver ischemia-reperfusion injury by activating the JAK2/STAT3/HAX1 pathway to regulate endoplasmic reticulum stress.

Yue P, Lv X, You J, Zou Y, Luo J, Lu Z Cell Mol Biol Lett. 2023; 28(1):55.

PMID: 37438690 PMC: 10337067. DOI: 10.1186/s11658-023-00466-5.